G
Glazer Capital, LLC
+ HoldingCVAC
+0.85%
3M Return
$4.660
-0.010 (-0.21%)Al cierre
Loading chart…
- High
- 4.665
- Open
- 4.570
- VWAP
- 4.63
- Vol
- 1.15M
- Mkt Cap
- 753.67M
- Low
- 4.570
- Amount
- 5.32M
- EV/EBITDA, TTM
- -4.64
CureVac CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Métricas de valoración
The current forward P/E ratio for CureVac NV (CVAC) is -7.85, compared to its 5-year average forward P/E of -7.79.
Whales holding CVAC
Cronología de eventos
Noticias
7.012-22BenzingaHoneywell Lowers FY2025 EPS Guidance to $9.70-$9.80 Amid Business Unit Discontinuation
8.512-22BenzingaClearwater Analytics (CWAN) Acquired by Private Equity Consortium for $8.4 Billion
8.512-18GlobenewswireBioNTech Completes CureVac Acquisition with 86.75% Shares Tendered
8.512-18NewsfilterBioNTech Completes CureVac Acquisition with 86.75% Shares Tendered
2.012-16NASDAQ.COMCureVac Falls into Oversold Zone (CVAC)
CVAC FAQ — answered by Alphio AI
CureVac CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.